Related Experiment Video
Updated: Sep 19, 2025

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
Published on: April 17, 2013
TSHR in thyroid cancer: bridging biological insights to targeted strategies
Abstract:
Traditionally, thyroid-stimulating hormone receptor (TSHR) has been utilized primarily to increase the efficacy of radioactive iodine therapy by promoting iodine uptake. However, the rise of personalized medicine has prompted reassessment of the potential of TSHR as a therapeutic target. Recent studies have indicated that TSHR plays a critical role in the progression of thyroid cancer and may serve as a key target for the treatment of residual or metastatic thyroid cancers, particularly radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). This review focuses on the biological characteristics of TSHR and its potential as a therapeutic target, emphasizing that optimizing TSHR-targeted drugs and integrating them with existing treatment strategies could offer new therapeutic avenues for patients with RAIR-DTC.
Insights
Thyroid-stimulating hormone receptor (TSHR) is a potential target for thyroid cancer treatment. Optimizing TSHR-targeted drugs may offer new options for radioiodine-refractory differentiated thyroid cancer.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Thyroid-stimulating hormone receptor (TSHR) traditionally enhances radioactive iodine therapy efficacy by increasing iodine uptake.
- Personalized medicine trends necessitate re-evaluating TSHR's therapeutic potential beyond its traditional role.
Purpose of the Study:
- To review the biological characteristics of TSHR.
- To explore TSHR's potential as a therapeutic target for thyroid cancer, especially radioiodine-refractory differentiated thyroid cancer (RAIR-DTC).
Main Methods:
- Literature review focusing on TSHR's role in thyroid cancer progression.
- Analysis of TSHR's potential as a therapeutic target in the context of personalized medicine.
Main Results:
- TSHR plays a critical role in thyroid cancer progression.
- TSHR is a promising target for treating residual or metastatic thyroid cancers, particularly RAIR-DTC.
Conclusions:
- Optimizing TSHR-targeted drugs is crucial.
- Integrating TSHR-targeted therapies with existing strategies may provide new treatment avenues for RAIR-DTC patients.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Tumor Immunotherapy
Functions of Thyroid Hormones
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
Mitogens and the Cell Cycle
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

